This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

GF

You have email. Pick up asap.

MS

From the other side.

A0469514 - 6 Sep'06 - 13:30 - 7658 of 7661


I agree with el magnifico that a full bid for MMG is very unlikely given the number of shares controlled by Best and his wife. It is however very plausible that Glaxo would be in the forefront of negotiations for a slice of the action in some of MMG's product pipeline. Genvax, in particular, would seem to fit very well into GSK's vaccines business which they have been expanding aggressively in recent years.

I suppose that Best could agree to sell MMG's stake in the Genvax programme to the highest bidder and distribute the proceeds to shareholders via a special dividend. However Best would pay an awfull lot of tax doing it that way so it is unlikely.

By far the most likely imo is a deal where someone like Glaxo takes on the further development and future marketing of Genvax and pays an upfront fee, milestone payments as development progresses and then royalties on product sales. In that way MMG's shareprice would receive a massive boost and, if Best's confidence in his product is justified, it would carry on improving in the years ahead when it becomes clear that the products will hit the market and likely be blockbusters.

The problem is that when you are negotiating with 9 of the top ten pharma companies it is certainly not going to be a quick process and it is very difficult to predict when a deal may be clinched. My guess though is that both the Genvax and ruthenium programmes are close to a stage where some big money and a heavyweight partner could be very useful to Best's ambitions for the company. For this reason, I believe that the announcement of a huge deal could be close.

Xylos

Cheers for the info on Glaxo Mitzey.

Mickey, PM gone through to you.

GF

You are a star. Many thanks for that. Several pints of Stella coming your way.

LOL
MS

hi guys... with MMG from 300p, looking forwards 220p in short futher.. any chance? thanks
swseun

AGM is due end of the month so DB will update us on the latest Glaxo rumour.

Cheers lads. Im just supping my stella. By the way the PM was nothing re- to MMG.

From the other place. The next 12 months are going to be interesting. If you fancy a blue sky stock then this is the one. A cure for cancer, what's that worth, billions. Any news of a tie up and this will rocket, but patience will be needed and rewarded. LOL

M25 - 20 Sep'06 - 22:54 - 7705 of 7712


AGM Update -
A few of my observations.
DB stated that all 3 technologies continue to show positive indications and a point he reiterated more than once throughout his presentation was that if there were any bad news, it would be disclosed immediately.
He stated that with the 3 technology platforms, there were effectively 3 chances of hitting the jackpot.
Now the nitty gritty.

Genvax
(Intersting to note DNA vaccines appears 1st in order in MMI AGM Report).

Further patents have been granted on their Lung and colon cancers. (No RNS needed as there are so many patents already).
2 new scientists have been appointed to assist with the tuberculosis vaccine and I got the impression DB rather likes this one as he mentioned it several times throughout his speech.
The Lymphoma vaccine was mentioned in that the market had grown rapidly to be worth 3bn currently.
MMI are in talks with a US co(emphasised because that is the key market for the vaccine). I also got the impression the progression to PIIb would be with a partner.
Prostate PIIa trial results expected before year end.
Because of the regulatory framework, MMI is unable to show shareholders preliminary results which was mentioned a few times in the Q&A by Michael Walters I believe.

Oncosense
8 week setback with Ru trial start due to impurities.
Now expected to commense Jan 07.
Stability testing is ongoing and has so far proved ok.
The 3rd Ru compound (4414) has been dropped in favour of 4417 due to complicated and expensive manufacturing process.
2nd generation Ru drugs being developed using computers to optimise efficacy.
A question was raised against this statement which was cleverly fielded by Dr James Brenton in that Cisplatin first entered clinical tials in the 1970s. It is still in trials today used in conjunction with other therapies due to its good properties.

Viratis
Lots of progress but still a long way from clinic and adding real value so nothing much to report.

Overall
David was non-commital when pressed about partnerships etc.
When pushed on a question, "Could you have had a deal by now if you had wanted" was met by a reluctant yes (said with a glance towards the advisors).
Same chap also asked if the shareholders would have a good Xmas. David said that he planned to (with his family).
DB was quite jovial and relaxed which to me indicates his strong position and he also added several non top 10 pharmas had joined the table, although which table he did not say.
He described them as special situations.

Can see less reason to sell now than yesterday but then i don't day trade these.



BennytheBall - 20 Sep'06 - 23:02 - 7706 of 7712


Feedback, yes. After the formal bit of the meeting (all resolutions passed), there was a presentation by David Best and then Q&As with DB and the board.

The presentation elaborated on the content of the 'Latest Portfolio Developments' RNS this morning, drawing out a few interesting themes such as
- H5N1 (and HPV) vaccine developments, misleading spin and MMI's strong position in the industry
- Viratis' sudden acceleration through the invention of a successful delivery mechanism
- details of a 6 week delay in the Ruthenium trial programme
- Genvax retaining their focus on lucrative bespoke vaccines, at the same time as developing tumour-type specific and now broad range cancer vaccines
- Data from 1st generation Genvax trials (bespoke vaccines) complete and now being analysed [presumably formal confirmation of what we've been excited about since March 2005]
- Commencement of Ruthenium phase II trials to follow on the successful outcome of a research ethics committee submission in January 2007
- I'm sure there were one or two other striking points, but I can't be arsed to find my notes, as I'm knackered. Others can fill in.

In the Q&A bit, despite all of our efforts to draw David Best on the timing of the coming news of developments in the science or commercialisation, he remained calm, contained and professional.

He assured us that
- all was on track
- there had been dialogue with more than nine pharmas (but only nine of the biggest ten)
- we are more likely to glean there has been clinical progress through RNSs about deals than through RNSs about clinical progress, since MMI can share incomplete/pre-audited clinical data under NDAs with commercial partners ('insiders') that would not be releasable as RNSs for research ethics reasons, and such incomplete/pre-audited data is likely to drive deals
- a deal rather than clinical milestones may thus be the next thing to drive the price
- a deal could probably have been done by now if the board had not wanted to maximise the long term value of the company
- some of the interest from pharmas may have been driven by wanting to kill the competition rather than develop the product
- no news is good news - it means long-winded trials are progressing without any of the sequentially-recruited patients getting worse, and MMI continue to anticipate deals at the point where the deal value is optimised by research progress
- we can look forward to Christmas

;-)

I'd be interested to hear of any conversations with DB or board members I missed after leaving in a hurry at the end.

Ben

so where is MMG going to now? anyone?

A nice little 4% today. GF you still in?

MS

Sorry 5%.Opps

MS

nice to see it up.. will it last long? fly over 300p? or practice its up and down again??

At DB's last meeting in Sept I think it was, he said he expects to increase shareholder value significantly this year. If they sign a deal with one of the big boys then this will fly way past 3. Be patient and hold your nerve.

LOL
MS

Thanks mickeyskint,
I guess it will happen in last Nov.. just pure guess.. coz MMG always move slow.
Wish it is not too late to top up next monday (coz friday 13th is not my day) !! :-)

Good day to day. Mickey is Evil still in these?, Id ring him but last I heard I think hes gone on a piss up to Norfolk as he usually does this time of year on his birthday.

Moving up.

GF

Yes he is still in. When they get a deal with one of the big boys thses will fly. I think there is only 50 mil shares in issue and DB holds a fair chunk. The next 12 months will be very interesting.

LOL
MS

Fingers crossed.

Medical Marketing Int'l Group PLC
17 October 2006



Notification of Major Interests in Shares

October 17th 2006. Medical Marketing International Group plc ('Company') (AIM:
MMG) the UK virtual pharmaceutical development company focused on drugs for the
treatment of cancer and infectious diseases, received notification on 16th
October 2006 that Man Financial Limited is the beneficial owner of 2,331,700
ordinary shares of 0.2p in the Company representing 3.98% of the issued share
capital of the Company.


-ends-


Contacts

Medical Marketing International Group plc Brunswick Group LLP
David Best Justine McIlroy / Alex Tweed /
Executive Chairman Jon Coles
Tel. +44 (0) 207 404 5959
Rob Sprawson
Chief Financial Officer

Tel: +44 (0) 1223 477 677


About MMI Group

MMI is a virtual pharmaceutical development company that identifies, acquires
and develops world-class compounds and technologies from leading academic
organizations. These technologies are aimed at producing blockbuster drugs to
satisfy unmet needs in major therapeutic markets. The company manages the
preclinical and early clinical development of drug candidates before pursuing
licensing partners to manage late-stage development. Through its three platform
technologies MMI has a risk-balanced portfolio of compounds in development for
the treatment of cancer and infectious disease. Please visit

That made the share price value drop, isn't it?